×
EMA Says Sinus Bradycardia a Possible Risk With Remdesivir
https://www.medscape.com/viewarticle/952973

Jun 10th, 2021 - Following a safety review, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has recommended adding sinus bradycardia to the product label for remdesivir (Veklury) as an adverse reaction of "unknown frequency." At its February meeting, the safety committee announced that it has started a new "safety signal" procedure for remdesivir after the Italian M...

Mavrilimumab May Aid Severe COVID-19 Recovery
https://www.medscape.com/viewarticle/952941

Jun 10th, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Inhibiting granulocyte/macrophage–colony stimulating factor (GM-CSF) with mavrilimumab prevented some patients with severe COVID-19 pneumonia and hyperinflammation from needing mechanical ventilation and reduced their risk of dying versus placebo in a phase 2 study. There was no difference in ou...

Extubation Failure in Critically Ill COVID-19 Patients: Risk Factors and Impact on In-H...
https://doi.org/10.1177/08850666211020281
Journal of Intensive Care Medicine; Ionescu F, Zimmer MS et. al.

Jun 2nd, 2021 - We sought to identify clinical factors that predict extubation failure (reintubation) and its prognostic implications in critically ill COVID-19 patients. Retrospective, multi-center cohort study of hospitalized COVID-19 patients. Multivariate competing risk models were employed to explore the rate of reintubation and its determining factors. Two hundred eighty-one extubated patients were inclu...

Medication of Hydroxychloroquine, Remdesivir and Convalescent Plasma during the COVID-1...
https://doi.org/10.3390/ijerph18115685
International Journal of Environmental Research and Publi... Voit K, Timmermann C et. al.

Jun 2nd, 2021 - This paper aims to analyze the ethical challenges in experimental drug use during the early stage of the COVID-19 pandemic, using Germany as a case study. In Germany uniform ethical guidelines were available early on nationwide, which was considered as desirable by other states to reduce uncertainties and convey a message of unity. The purpose of this ethical analysis is to assist the preparati...

Asthma and COVID-19: An early inpatient and outpatient experience at a US children's ho...
https://doi.org/10.1002/ppul.25514
Pediatric Pulmonology; Farzan S, Rai S et. al.

Jun 1st, 2021 - Initially, persistent asthma was deemed a risk factor for severe COVID-19 disease. However, data suggests that asthmatics do not have an increased risk of COVID-19 infection or disease. There is a paucity of data describing pediatric asthmatics with COVID-19. The objectives of this study were to determine the prevalence of asthma among hospitalized children with acute symptomatic COVID-19, comp...

Black Market for Remdesivir Thwarts India's COVID Response
https://www.medscape.com/viewarticle/952278

Jun 1st, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. "Know anyone selling remdesivir. " messaged Rishi Khanna in a WhatsApp group "There's a risk of getting fake remdesivir from the illegal market, which would be bad for patients — financially and medically," Singh says. Wasn't he abetting the shadow market by verifying the quality of its product?...

Remdesivir for the treatment of Covid-19: the value of biochemical studies.
https://doi.org/10.1016/j.coviro.2021.04.014
Current Opinion in Virology; Götte M

May 30th, 2021 - The nucleotide analogue prodrug remdesivir remains the only FDA-approved antiviral small molecule for the treatment of infection with SARS-CoV-2. Biochemical studies revealed that the active form of the drug targets the viral RNA-dependent RNA polymerase and causes delayed chain-termination. Delayed chain-termination is incomplete, but the continuation of RNA synthesis enables a partial escape ...

An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopina...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149166
Clinical Microbiology and Infection : the Official Public... Ader F, Peiffer-Smadja N et. al.

May 28th, 2021 - We evaluated the clinical, virological and safety outcomes of lopinavir/ritonavir, lopinavir/ritonavir-interferon (IFN)-β-1a, hydroxychloroquine or remdesivir in comparison to standard of care (control) in COVID-19 inpatients requiring oxygen and/or ventilatory support. We conducted a phase 3 multi-centre open-label, randomized 1:1:1:1:1, adaptive, controlled trial (DisCoVeRy), add-on trial to ...

Role of OATP4C1 in Renal Handling of Remdesivir and its Nucleoside Analog GS-441524: Th...
https://doi.org/10.18433/jpps31813
Journal of Pharmacy & Pharmaceutical Sciences : a Publica... Sato T, Maekawa M et. al.

May 28th, 2021 - Remdesivir and its active metabolite are predominantly eliminated via renal route; however, information regarding renal uptake transporters is limited. In the present study, the interaction of remdesivir and its nucleoside analog GS-441524 with OATP4C1 was evaluated to provide the detailed information about its renal handling. We used HK-2 cells, a proximal tubular cell line derived from normal...

Safety and Efficacy of Remdesivir for the Treatment of COVID-19: A Systematic Review an...
https://doi.org/10.18433/jpps31870
Journal of Pharmacy & Pharmaceutical Sciences : a Publica... Tasavon Gholamhoseini M, Yazdi-Feyzabadi V et. al.

May 28th, 2021 - To evaluate the safety and efficacy of remdesivir in adult patients with COVID-19. PubMed, Embase, Scopus, Web of Science, Cochrane Library, ClinicalTrials.gov, and medRxiv databases were searched using a search strategy tailored to each database. The Consolidated Standards of Reporting Trials (CONSORT) and Strengthening the reporting of observational studies in epidemiology (STROBE) checklists...

Management of COVID-19 in patients with seizures: Mechanisms of action of potential COV...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132550
Epilepsy Research; Jain S, Potschka H et. al.

May 27th, 2021 - In regard to the global pandemic of COVID-19, it seems that persons with epilepsy (PWE) are not more vulnerable to get infected by SARS-CoV-2, nor are they more susceptible to a critical course of the disease. However, management of acute seizures in patients with COVID-19 as well as management of PWE and COVID-19 needs to consider potential drug-drug interactions between antiseizure drugs and ...

UK COVID-19 Update: Jabs for All, Hancock's Denial, GPs Under Pressure
https://www.medscape.com/viewarticle/951971

May 26th, 2021 - Editor's note, 27 May 2021: This article was updated with information from a Downing Street briefing. Previously the drug was recommended for patients on supplemental oxygen but not on invasive mechanical ventilation but the length of treatment remains at 5 days. NICE said evidence suggests that remdesivir is more beneficial earlier in the course of the disease. Hancock's Denial England's Healt...

Japan's special approval for emergency system during COVID-19 pandemic.
https://doi.org/10.1002/cpt.2310
Clinical Pharmacology and Therapeutics; Maeda H

May 25th, 2021 - The development of drugs for coronavirus disease 2019 (COVID-19) is a global challenge. In Japan, remdesivir was approved in May 2020 for COVID-19 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In February 2021, a vaccine against COVID-19 was approved. These two approvals were made using the Special Approval for Emergency system in Japan. This Japanese sys...

Inside the Race to Find a COVID-19 Treatment Pill
https://www.medscape.com/viewarticle/951629

May 23rd, 2021 - LOS ANGELES (Reuters) - In early 2020, as a new deadly coronavirus began spreading around the world, Pfizer Inc assembled what it called a "SWAT team" of scientists and chemists to identify a potential treatment to fight COVID-19. The U. S "Right now we have very good reason to believe that we can be successful," Bourla told an economic forum in Greece via video conference last week. Pfizer and...

Favipiravir use in children with COVID-19 and acute kidney injury: is it safe?
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140325
Pediatric Nephrology (Berlin, Germany); Ozsurekci Y, Oygar PD et. al.

May 22nd, 2021 - The rising number of infections due to Severe Acute Respiratory Syndrome Coronavirus-2 (popularly known as COVID-19) has brought to the fore new antiviral drugs as possible treatments, including favipiravir. However, there is currently no data regarding the safety of this drug in patients with kidney impairment. The aim of this paper, therefore, is to share our experience of the use of favipira...

Complicated case of COVID-19 disease with overlapping features of thrombotic thrombocyt...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137254
BMJ Case Reports; Verma DP, Dandu H et. al.

May 20th, 2021 - Haemophagocytic lymphohistiocytosis has been reported as an uncommon complication of severe COVID-19 disease while thrombotic thrombocytopenic purpura has been rarely reported. Here, we are reporting a 21-year-old man who developed a combination of these complications during the hospital stay in the post-COVID-19 recovery period. He presented with fever and bilateral COVID-19-related pneumonia ...

COVID-19: breaking down a global health crisis.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129964
Annals of Clinical Microbiology and Antimicrobials; Mallah SI, Ghorab OK et. al.

May 19th, 2021 - Coronavirus disease 2019 (COVID-19) is the second pandemic of the twenty-first century, with over one-hundred million infections and over two million deaths to date. It is a novel strain from the Coronaviridae family, named Severe Acute Respiratory Distress Syndrome Coronavirus-2 (SARS-CoV-2); the 7th known member of the coronavirus family to cause disease in humans, notably following the Middl...

Real life Study on the Pharmacokinetic of Remdesivir in ICU patients admitted for Sever...
https://doi.org/10.1111/bcp.14895
British Journal of Clinical Pharmacology; Corcione S, De Nicolò A et. al.

May 15th, 2021 - Remdesivir is one of the most encouraging treatments against SARS-CoV-2 infection. After intravenous infusion, RDV is rapidly metabolized (T1/2 1h) within the cells to its active adenosine triphosphate analogue form (GS-443902) and, then, it can be found in plasma in its nucleoside analogue form (GS-441524). In this real life study we describe the Remdesivir and GS-441524 concentrations at 3 ti...

Aerosolized nanoliposomal carrier of remdesivir: an effective alternative for COVID-19 ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117723
Nanomedicine (London, England); Vartak R, Patil SM et. al.

May 13th, 2021 - Aim: To formulate an aerosolized nanoliposomal carrier for remdesivir (AL-Rem) against coronavirus disease 2019. Methods: AL-Rem was prepared using modified hydration technique. Cytotoxicity in lung adenocarcinoma cells, stability and aerodynamic characteristics of developed liposomes were evaluated. Results: AL-Rem showed high encapsulation efficiency of 99.79%, with hydrodynamic diameter of 7...

Dietary Supplements for COVID-19.
https://doi.org/10.1007/978-3-030-63761-3_29 10.1136/rmdopen-2020-001295 10.1186/cc10495 10.3389/fimmu.2020.00602 10.1007/bf01317848 10.1016/j.heliyon.2020.e03814 10.1016/j.jcv.2010.12.006 10.1056/NEJMoa2007764 10.7759/cureus.8342 10.1016/j.jacc.2020.04.028 10.1186/s13054-019-2538-y 10.1186/s13054-020-02851-4 10.3390/nu9111211 10.1155/2014/426740 10.1172/JCI137244 10.23812/CONTI-E 10.1002/jcp.24729 10.1016/j.ejphar.2020.173329 10.1016/j.clim.2016.02.011 10.1128/IAI.73.4.1907-1916.2005 10.1001/jama.2019.11825 10.1001/jama.2019.21987 10.1056/NEJMoa2015301 10.3390/nu7064240 10.1186/s40779-020-00240-0 10.1186/s13063-019-3254-2 10.1001/jama.2019.21984 10.1080/22221751.2020.1770129 10.1016/j.phrs.2020.104921 10.1016/j.phrs.2020.104921 10.1177/2054270417694291 10.1136/bmjopen-2019-031662 10.1007/s12192-020-01126-9 10.1152/ajpendo.00150.2020 10.1016/S0140-6736(20)30183-5 10.1186/s13063-019-3542-x 10.3390/nu12061562 10.2174/0929867324666170227121619 10.2174/0929867324666170227121619 10.1016/j.clinthera.2015.04.004 10.26355/eurrev_202004_21036 10.6026/97320630009978 10.1016/j.jcrc.2018.07.004 10.3390/nu11122976 10.1152/ajpendo.00198.2020 10.1097/JCMA.0000000000000319 10.1186/s12879-017-2253-8 10.1136/bmj.m1036 10.1136/bmj.i6583 10.1007/s40415-016-0283-x 10.7326/0003-4819-125-2-199607150-00001 10.1016/j.phymed.2020.153238 10.1016/j.jacbts.2020.04.006 10.3390/jcm9040967 10.1007/s11011-018-0348-6 10.1097/CCM.0000000000001148 10.1093/advances/nmz013 10.3389/fmed.2020.00226 10.1016/j.anai.2010.01.013 10.1073/pnas.2003138117 10.3390/jcm8010102 10.1016/j.healun.2020.03.012 10.1155/2016/1045657 10.1371/journal.ppat.1001176 10.1002/rmv.2032 10.3233/RNN-201042 10.1186/s13063-019-3856-8 10.3389/fimmu.2020.01580 10.1016/j.cell.2020.02.058 10.1016/j.foodres.2019.108628 10.1172/jci.insight.137799 10.1002/jmv.25748 10.1016/S0140-6736(20)31022-9 10.3390/nu7105392 10.7861/clinmed.2020-0301 10.1016/j.jmii.2020.03.005 10.1371/journal.pone.0109180 10.1002/rmv.1909 10.1093/cvr/cvz312 10.1016/S0140-6736(20)30566-3
Advances in Experimental Medicine and Biology; Mullin GE, Limektkai B et. al.

May 11th, 2021 - Coronavirus disease 2019 (COVID-19) is a highly contagious infectious disease that can rapidly escalate to respiratory failure and death. It has infected millions of people worldwide. The trajectory of this disease continues to progress in some areas of the United States and worldwide. The Institute for Health Metrics now predicts a resurgence of infections in the fall of 2020. The pathogenesis...